Kailera Therapeutics (NASDAQ:KLRA) Shares Gap Up – What’s Next?

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) gapped up prior to trading on Friday . The stock had previously closed at $20.99, but opened at $21.91. Kailera Therapeutics shares last traded at $20.53, with a volume of 116,954 shares.

Wall Street Analyst Weigh In

KLRA has been the subject of several recent research reports. TD Cowen began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price target for the company. William Blair initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating for the company. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Zacks Research raised Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Down 6.1%

Insiders Place Their Bets

In related news, Director Andrew T. Kaplan acquired 8,398,438 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. The trade was a 47.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adam Koppel acquired 1,562,500 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $25,000,000.00. Following the completion of the transaction, the director owned 22,583,268 shares in the company, valued at $361,332,288. The trade was a 7.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.